Modulation of nitric oxide production in RAW 264.7 cells by transforming growth factor-beta and interleukin-10: Differential effects on free and encapsulated immunomodulator

Journal of Leukocyte Biology

Volumn 62, Issue 3, 1997, Pages 374-380

  Seyler, Isabelle ^a   Appel, Martine ^a   Devissaguet, Jean Philippe ^a   Legrand, Philippe ^a   Barratt, Gillian ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Macrophage activation; Muramyldipeptide; Nanocapsules; NO synthase; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; MURAMYL TRIPEPTIDE; NITRIC OXIDE; POLYGLACTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FEEDBACK SYSTEM; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALIA;

EID: 0030818017     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.62.3.374     Document Type: Article

References (37)

1. Hibbs, J., Taintor, R. R., Vavrin, Z., Rachlin, E. M. (1988) Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157, 87-94.
2. Stuehr, D. J., Nathan, C. F. (1989) A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169, 1543-1555.
3. Albina, J. (1995) On the expression of nitric oxide synthase by human macrophages. Why no NO. J. Leukoc. Biol. 58, 643-649.
4. Drapier, J. C., Hibbs, J. B., Jr. (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J. Immunol. 140, 2829-2838.
5. Messmer, U. K., Lapetina, E. G., Brune, B. (1995) Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C-and protein kinase A-activating compounds. Mol. Pharmacol. 47, 757-765.
6. Bogdan, C., Nathan, C. (1993) Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann. N.Y. Acad. Sci. 685, 713-739.
7. Oswald, I. P., Gazzinelli, R. T., Sher, A., James, S. L. (1992) IL-10 synergises with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J. Immunol. 148, 3578-3582.
8. Barratt, G. M., Raddassi, K., Petit, J.-F., Tenu, J.-P. (1991) MDP and LPS act synergistically to induce an arginine-dependent cytostatic activity in rat alveolar macrophages. Int. J. Immunopharmacol. 13, 159-165.
9. Morin, C., Barratt, G., Fessi, H., Devissaguet, J. P., Puisieux, F. (1994) Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. Int. J. Immunopharmacol. 16, 451-456.
10. 125I-labelled aryl-azide derivatives of muramyldipeptide. Int. J. Immunopharmacol. 11, 653-661.
11. Seyler, I., Appel, M., Devissaguet, J. P., Legrand, P., Barratt, G. (1996) Relationship between NO-synthase and TNF-α secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int. J. Immunopharmacol. 18, 385-392.
12. Mehri, G., Coleman, A. W., Devissaguet, J. P., Barratt, G. M. (1996) Synthesis and immunomodulating properties of lipophilic ester and ether muramyl peptide derivatives. J. Med. Chem. 39, 4483-4488.
13. Devissaguet, J. P., Fessi, H., Puisieux, F. (1991) Process for the preparation of dispersible colloidal systems of a substance in the form of nanocapsules. U.S. Patent 5,049,322.
14. Seyler, I., Morin, C., Barratt, G. M., Devissaguet, J.-R. Puisieux, F. (1995) Induction of macrophage NO-synthase by an immunomodulator entrapped within polymeric nanocapsules. Eur. J. Pharmaceut. Biopharmaceut. 41, 47-54.
15. 2-Macroglobulin functions as a cytokine carrier to induce nitric oxide synthesis and causes nitric oxide-dependent cytotoxicity in the RAW 264.7 macrophage cell line. J. Biol. Chem. 270, 21919-21927.
16. 15N) nitrate in biological fluids. Anal. Biochem. 126, 131-138.
17. Bottalico, L. A., Wager, R. E., Agellon, L. B., Assoian, R. K., Tabas, I. (1991) Transforming growth factor-β1 inhibits scavenger receptor activity in THP-1 human macrophages. J. Biol. Chem. 266, 22866-22871.
18. Hampton, R. Y., Golenbock, D. T., Penman, M., Krieger, M., Raetz, C. R. H. (1991) Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 352, 342-344.
19. Kekow, J., Wiedeman, G. J. (1995) Transforming growth factor β: A cytokine with multiple actions in oncology and potential clinical applications (Review). Int. J. Oncol. 7. 177-182.
20. Assoian, R. K., Fleurdelys, B. E., Stevenson, H. C., Miller, P. J., Madtes, D. K., Raines, E. W. Russell, R., Sporn, M. B. (1987) Expression and secretion of type β transforming growth factor by activated human macrophages. Proc. Natl. Acad. Sci. USA 84, 6020-6024.
21. Haak-Frendscho, M., Wynn, T. A., Czuprynski, C. J., Paulnock, D. (1990) Transforming growth factor-β1 inhibits activation of macrophage cell line RAW 264.7 for cell killing. Clin. Exp. Immunol. 82, 404-410.
22. Corradin, S. B., Buchmuller-Rouiller, Y. Smith, J., Suardet, L., Mauël, J. (1993) Transforming growth factor β1 regulation of macrophage activation depends on the triggering stimulus. J. Leukoc. Biol. 54, 423-429.
23. Hirsch, G. S., Yoneda, T., Averill, L., Ellner, J. J., Toossi, Z. (1994) Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-β1. J. Infect. Dis. 170, 1229-1237.
24. Hausmann, E. H. S., Hao, S., Pace, J. L., Parmely, M. J. (1994) Transforming growth factor-β1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages. Infect. Immunol. 62, 3625-3632.
25. Ding, A., Nathan, C. F., Grayear, J., Derynck, R., Stuehr, D. J., Srimal, S. (1990) Macrophage deactivating factor and transforming growth factor-β1, -β2, and -β3 inhibit induction of macrophage nitrogen oxide synthesis by interferon-γ. J. Immunol. 145, 940-944.
26. Försterman, U., Schmidt, H. H. H. W., Kohlhaas, K. L., Murad, F. (1992) Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-β. Eur. J. Pharmacol. 225, 161-165.
27. Vodovotz, Y., Bodgan, C., Paik, J., Xie, Q., Nathan, C. (1993) Mechanism of suppression of macrophage nitric oxide release by transforming growth factor-β. J. Exp. Med. 178, 605-613.
28. Gilbert, R. S., Herschman, H. R. (1993) Transforming growth factor beta differentially modulates the inducible nitric oxide synthase gene in distinct cell types. Biochem. Biophys. Res. Commun. 195, 380-384.
29. 2. J. Immunol. 153, 1674-1686.
30. Miller-Graziano, C. L., Szabo, G., Griffey, K., Mehta, B., Kodys, K., Catalano, D. (1991) Role of elevated monocyte transforming growth factor-β (TGF-β) production in posttrauma immunosuppression. J. Clin. Immunol. 11, 95-102.
31. Nunes, I., Shapiro, R. L., Rifkin, D. B. (1995) Characterization of latent TGF-β activation by murine peritoneal macrophages. J. Immunol. 155, 1450-1459.
32. Vodovotz, Y., Letterio, J. L., Geiser, A. G., Chesler, L., Roberts, A. B., Sparrow, J. (1996) Control of nitric oxide production by endogenous TGF-β and systemic nitric oxide in retinal pigment epithelial cells and peritoneal macrophages. J. Leukoc. Biol. 60, 261-270.
33. Bogdan, C., Vodovotz, Y., Nathan, C. (1991) Macrophage deactivation by interleukin-10. J. Exp. Med. 174, 1549-1555.
34. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., O'Garra, A. (1991) IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815-3822.
35. Fidler, I. J., Kleinerman, E. S. (1993) Therapy of cancer metastasis by systemic activation of macrophages: From the bench to the clinic. Res. Immunol. 144, 283-287.
36. Barratt, G., Puisieux, F., Yu, W.-P. Foucher, C., Fessi, H., Devissaguet, J. P. (1994) Anti-metastatic activity of MDP-L-alanyl CHOL incorporated into various types of nanocapsules. Int. J. Immunopharmacol. 16, 457-461.
37. Asano, T., Kleinerman, E. S. (1993) Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J. Immunother. 14, 286-292.